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How Stricter E-Cigarette Regulations 




First harvested for export in 1612, tobacco has remained a large, and controversial, 
part of the United States’ identity. In 1966, 42.6% of the American population 
smoked cigarettes. Currently, cigarette usage rate is around 14%, its lowest rate 
ever. Even with this sharp decline, cigarettes remain the number one cause of pre-
ventable deaths in the United States resulting in approximately 480,000 deaths per 
year. Nicotine, the active ingredient in tobacco, is an addictive drug, and many treat-
ments exist for those attempting to quit. Recent studies have shown, however, that 
electronic nicotine delivery systems, more commonly known as “vapes” or “e-cig-
arettes”, are more effective than the other forms of commonly used cigarette cessa-
tion devices. E-cigarettes have been marked by their own controversy, however, as 
they have shown to be exceedingly popular among adolescents. Due to the high 
underage use, many states began implementing their own regulations or bans on e-
cigarettes, with the federal government eventually stepping in to attempt to limit 
underage use. These attempts may have the consequential side-effects of leading 
those using e-cigarettes as a cessation device to return to using traditional cigarettes 
and adding a barrier to current cigarette smokers wanting to quit. To remedy this, I 
propose that the United States Food and Drug Administration (“FDA”) provide e-
cigarettes with a specialized Over-the-Counter monograph that would allow adults 
access to what has shown to be an incredible cigarette cessation tool, while also 








* Tyler Manuel is a second-year student at the University of Missouri School of Law. Prior to entering 
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I.     INTRODUCTION 
A. The FDA’s Regulatory Authority of E-Cigarettes 
In 1996, the Food and Drug Administration (“FDA”) attempted to assert juris-
diction over the regulation of tobacco products by claiming that nicotine is covered 
under the “drug” definition in the Federal Food, Drugs, and Cosmetics Act 
(“FDCA”).1 If so, cigarettes and smokeless tobacco are drug-device combinations 
as they are devices delivering nicotine to the body.2 The FDA then promulgated 
regulations regarding the promotion, labeling, and accessibility of tobacco products 
in an attempt to decrease nicotine usage.3 In response to these regulations, tobacco 
manufacturers, retailers, and advertisers filed suit against the FDA, leading to the 
2000 Supreme Court case Food and Drug Administration v. Brown & Williamson 
Tobacco Corp.  (“Brown”).4 In Brown, the Court held that “the FDA’s claim to 
jurisdiction contravenes the clear intent of Congress”5 because Congress had al-
ready spoken directly on the issue of tobacco product regulation by enacting to-
bacco specific legislation that did not involve the FDA.6 Examples of such Con-
gressional action include  the Federal Cigarette Labeling and Advertising Act 
(“FCLAA”), which regulates cigarettes and “little cigars”,7 and the Comprehensive 
Smokeless Tobacco Health Education Act of 1986 (“CSTHEA”), which regulates 
smokeless tobacco.8 The Court reasoned that since one main purpose of the FDCA 
is to ensure that FDA regulated products are “‘safe’ and ‘effective’ for [their] in-
tended use,”9 the FDA would have to ban tobacco products, which are “the single 
leading cause of preventable death in the United States.”10 Further, the risk tobacco 
products posed to public health precludes a finding that tobacco products can be 
safe for their intended use.11 Since the adverse health effects of tobacco products 
were already well known when Congress enacted the FCLAA and the CSTHEA,12 
and Congress still decided to regulate the products as oppose to banning them, the 
Court concluded that it would be directly adverse to congressional intent for the 
 
 1. Food, Drug, and Cosmetic Act, ch. 675, Ch. II, § 201(g)(1), Pub. L. No. 111-31., 123 Stat. 1807 
(1938) (codified as amended at 21 U.S.C. § 321(g)(1) (2021)). (“The term ‘drug’ means (A) articles 
recognized in the official United States Pharmacopœia, official Homœopathic Pharmacopœia of the 
United States, or official National Formulary, or any supplement to any of them; and (B) articles intended 
for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; 
and (C) articles (other than food) intended to affect the structure or any function of the body of man or 
other animals; and (D) articles intended for use as a component of any article specified in clause (A), 
(B), or (C). . . .”). 
 2. Food and Drug Admin. v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 127 (2000), super-
seded by statute, Family Smoking Prevention and Tobacco Control Act of 2009, Pub. L. No. 111-31, 
123 Stat. 1776, as recognized in Big Time Vapes, Inc. v. FDA, 963 F. 3d 436 (5th Cir. 2020). 
 3. See id. at 128. 
 4. Id. at 129-30. 
 5. Id. at 132. 
 6. See 15 U.S.C. § 1331 (2018). 
 7. See id. 
 8. Brown, 529 U.S. at 156; 15 U.S.C. § 4401 (2018). 
 9. Brown, 529 U.S. at 133-34; see also 21 U.S.C. § 393(b)(2) (2018). 
 10. Brown, 529 U.S. at 134-135. 
 11. See id. at 135. 
 12. See id. at 138. 
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FDA to have jurisdiction over tobacco products as the agency would be required to 
ban them under the FDCA.13 
The FDA’s authority to regulate tobacco products comes from the enactment 
of the Family Smoking Prevention and Tobacco Control Act (“TCA”) on June 22, 
2009, which amended the FDCA to include tobacco products.14 Before this, tobacco 
products were only covered by the FDA in instances where the manufacturers made 
health claims about their tobacco product.15 
Although the TCA gave the FDA jurisdiction over tobacco products, the 
amendment did not necessarily mean that the FDA could outright ban tobacco prod-
ucts for lack of safety, as may be surmised by Brown. The TCA gave the FDA 
jurisdiction to regulate all tobacco products as tobacco products, not as drugs or 
medical devices.16 As such, the FDA no longer has to rely on the argument that such 
products are a drug or device to gain jurisdictional authority.17 
The TCA “excludes from the meaning of ‘tobacco product’ any ‘article that is 
a drug under 21 U.S.C. § 321(g)(1), a device under 21 U.S.C. § 321(h), or a com-
bination product described in 21 U.S.C. § 353(g).”18 As discussed in Brown, if the 
tobacco product is deemed to be a drug, a device, or a combination product, then 
the tobacco product must be banned under the FDCA.19 This exclusion provision 
would be satisfied when a manufacturer of a tobacco product markets the product 
in a way that is outside the existing marketing standards set by tobacco specific 
legislation,20 such as a claim of the product being a weight-loss aid or as a cessation 
device from traditional cigarettes.21 
The FDA defines an e-cigarette as “an electronic device that delivers e-liquid22 
in aerosol form into the mouth and lungs when inhaled.”23 Under this definition, 
there are two types of devices, open e-cigarettes, devices where the user can refill 
with their own e-liquid, and closed e-cigarettes, which are not intended to be refilled 
and include disposable e-cigarettes and replaceable cartridge based devices.24 The 
 
 13. See id. at 137-39. 
 14. Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems: Guidance for 
Industry, FOOD AND DRUG ADMINISTRATION: CENTER FOR TOBACCO PRODUCTS 3 (June 2019), 
https://www.fda.gov/media/127853/download [hereinafter Premarket Tobacco Product Applications]. 
 15. See Federal Regulation of Tobacco: A Summary, TOBACCO CONTROL LEGAL CONSORTIUM 2 
(July 2009), https://www.publichealthlawcenter.org/sites/default/files/resources/tclc-fda-summary.pdf. 
 16. See generally 21 U.S.C. §393(b)(2) (providing guidelines when tobacco products could be regu-
lated). 
 17. See generally id. (eliminating the drug or device requirement for regulation). 
 18. Smoking Everywhere, Inc. v. U.S. Food and Drug Admin., 680 F. Supp. 2d 62, 67 (D.D.C. 
2010), aff’d sub nom. Sottera, Inc. v. Food & Drug Admin., 627 F.3d 891 (D.C. Cir. 2010). 
 19. Food and Drug Admin. v. Brown & Williamson Tobacco Corp., 529 U.S. 120, 142 (2000), super-
seded by statute, Family Smoking Prevention and Tobacco Control Act of 2009, Pub. L. No. 111-31, 
123 Stat. 1776, as recognized in Big Time Vapes, Inc. v. FDA, 963 F. 3d 436 (5th Cir. 2020). 
 20. See e.g. Federal Cigarette Labelling and Advertising Act (FCLAA)., Pub. L. No. 89-92, 79 Stat. 
282 (1965) (codified as amended at 15 U.S.C. § 1331 (2018)); Comprehensive Smokeless Tobacco 
Health Education Act (CSTHEA), Pub. L. No. 99-252, 100 Stat. 30 (1986) (codified as amended at 15 
U.S.C. § 4401 (2018)). 
 21. See Smoking Everywhere, 680 F. Supp. 2d at 67-68. 
 22. Premarket Tobacco Product Applications, supra note 14, at 6 (Definition of e-liquid: “e-liquids 
include liquid nicotine, nicotine- containing liquids (i.e., liquid nicotine combined with colorings, fla-
vorings, and/or other ingredients), and liquids that do not contain nicotine or other material made or 
derived from tobacco, but that are intended or reasonably expected to be used with or for the human 
consumption of a tobacco product.”) 
 23. Id. 
 24. Id. 
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FDA classifies both e-cigarettes and e-liquids as covered under the general term 
Electronic Nicotine Delivery System (“ENDS”).25 
As ENDS were not explicitly included in the TCA, it was unclear whether they 
were considered tobacco products and were to be regulated the same as traditional 
tobacco products, or as drug-device combination.26 In the 2012 case Smoking Eve-
rywhere v. U.S. Food and Drug Administration (Smoking Everywhere), American 
e-cigarette distributers Smoking Everywhere and NJOY sued the FDA as a result 
of their 2008 refusal to allow importation of e-cigarettes.27 The FDA contended that 
the imported e-cigarettes were “intended to affect the structure or function of the 
body, and to prevent, mitigate, or treat the withdrawal symptoms of nicotine addic-
tion,”28 making the e-cigarettes an unapproved drug-device combination under the 
FDCA.29 The FDA argued that e-cigarettes were outside the scope of Brown & Wil-
liamson as neither the FLCAA nor the CSTHEA applied to e-cigarettes, and were 
not covered by the TCA.30 The court responded that “this argument is bootstrapping 
run amuck”31 and that Congress intended the TCA to cover non-traditional tobacco 
products because in the act they both single out traditional tobacco products and use 
the broader term “tobacco product.”32 
As a result of this clarification, on May 10, 2016 the FDA issued a final rule 
clarifying that their authority extends to any product that “meet(s) the statutory def-
inition of ‘tobacco product’ in section 201(rr) of the FD&C Act,” which includes 
ENDS products.33 Any new tobacco product, as defined under FDCA § 910,34 must 
undergo premarket review through either the manufacturer showing that the product 
is exempt from premarket review, the product is substantially equivalent to a non-
new tobacco product, or filing a premarket tobacco application (PMTA).35 In Au-
gust of 2017, the FDA issued guidance announcing that it will not enforce the pre-
market review provision for ENDS products until 2022.36 This guidance was va-
cated in the 2019 case American Academy of Pediatrics v. FDA amidst the backdrop 
of an alarming adolescent usage rate of ENDS products and a new lung disease 
affecting e-cigarette users.37 The court ordered manufacturers to submit their 
 
 25. Id. 
 26. See id. at 63-67. 
 27. Id. 
 28. Id. at 67-68. 
 29. Id. at 68. 
 30. Id. at 71. 
 31. Id. at 70. 
 32. Id. at 71. 
 33. Id. at 3. 
 34. “Any tobacco product that was not commercially marketed in the United States as of February 15, 
2007; or any modification of a tobacco product where the modified product was commercially marketed 
in the United States after February 15, 2007,” Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910, 
Pub. L. No. 111-31., 123 Stat. 1807 (1938) (codified as amended at 21 U.S.C. § 387(j) (2019)). 
 35. See 21 U.S.C. § 387(j)(2) (2019). 
 36. Am. Acad. of Pediatrics v. Food and Drug Administration, 379 F. Supp. 3d 461, 468 (D. Md. 
2019). 
 37. Id.; see also Teresa W. Wang et al., E-Cigarette Use Among Middle and High School Students – 
United States, 2020, 69 MORBIDITY & MORTALITY WEEKLY REPORT 1310, 1310 (Sep. 18, 2020) (stating 
that “[i]n 2020, approximately one in five high school students and one in 20 middle school students 
currently used e-cigarettes. By comparison, in 2019, 27.5% of high school students (4.11 million) and 
10.5% of middle school students (1.24 million) reported current e-cigarette use.”); E-cigarette or Vaping 
Product Use-Associated Lung Injury (EVALI), YALE MEDICINE, https://www.yalemedicine.org/condi-
tions/evali/ (last visited April 1, 2021) [hereinafter E-cigarette or Vaping Product Use-Associated Lung 
Injury (EVALI)]; FDA Issues Proposed Rule for Premarket Tobacco Product Applications as Part of 
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PMTAs by May 12, 2020.38 This May 12th deadline was then extended to Septem-
ber 9, 2020 to provide manufactures relief from varying complications in filling out 
their PMTAs stemming from the coronavirus pandemic.39 
B. The Current E-Cigarette Market 
E-cigarettes were invented by Chinese pharmacist, Hon Lik, in 2003, and in-
troduced to the American market in 2007.40 In the 13-years that these devices have 
been on the U.S. market, e-cigarettes have grown into a 4.2 billion USD industry as 
of 2018, with an expected compound annual growth rate of 24.1% from 2019 to 
2025, and a 12.41 billion USD valuation worldwide as of 2019.41 In recent years, 
there has been a staggering increase in adolescent use of e-cigarettes, with a 2020 
study revealing that “19.6% of high school students (3.02 million) and 4.7% of mid-
dle school students (550,000) reported current e-cigarette use.”42 
Although experts generally agree that ENDS products are less harmful than 
traditional cigarettes, the long-term effects of the products are still unclear.43 In Au-
gust of 2019, the Centers for Disease Control (“CDC”) identified a lung disease, 
later named EVALI, that was linked to the use of e-cigarettes.44 By February 18, 
2020, there were a total of 2,807 hospitalizations or deaths in the United States re-
sulting from EVALI, and the American Medical Association urged the public to 
avoid the use of e-cigarettes entirely.45 Amidst this outbreak and the high rate of 
 
Commitment to Continuing Strong Oversight of E-cigarettes and Other Tobacco Products , FOOD AND 
DRUG ADMINISTRATION, (Sep. 20, 2019) https://www.fda.gov/news-events/press-announcements/fda-
issues-proposed-rule-premarket-tobacco-product-applications-part-commitment-continuing-strong. 
 38. Am. Acad. of Pediatrics, 379 F. Supp. 3d at 468. 
 39. See Coronavirus (COVID-19) Update: Court Grants FDA’s Request for Extension of Premarket 
Review Submission Deadline for Certain Tobacco Products Because of Impacts from COVID-19, FOOD 
AND DRUG ADMINISTRATION (April 23, 2020), https://www.fda.gov/news-events/press-announce-
ments/coronavirus-covid-19-update-court-grants-fdas-request-extension-premarket-review-submis-
sion-deadline. 
 40. Rachel Grana et al., Background Paper on E-cigarettes (Electronic Nicotine Delivery Systems), 
CENTER FOR TOBACCO CONTROL RESEARCH AND EDUCATION 6 (Dec. 2013), https://escholar-
ship.org/uc/item/13p2b72n#page=6. 
 41. GRAND VIEW RESEARCH, U.S. E-cigarette And Vape Market Size, Share & Trends Analysis Re-
port By Component, By Distribution Channel, By Product (Rechargeable, Disposable, Modular), And 
Segment Forecasts, 2019 – 2025, (June 2019) https://www.grandviewresearch.com/industry-analysis/e-
cigarette-vaping-market; GRAND VIEW RESEARCH, E-cigarette And Vape Market Size, Share & Trends 
Analysis Report By Product (Disposable, Rechargeable), By Component (Vape Mod, E-liquid), By Dis-
tribution Channel, And Segment Forecasts, 2020 – 2027, (Feb. 2020) https://www.grandviewre-
search.com/industry-analysis/e-cigarette-vaping-market. 
 42. Wang et al., supra note 37, at 1310. 
 43. See generally David T. Levy et al., Potential Deaths Averted in USA by Replacing Cigarettes With 
E-cigarettes, TOBACCO CONTROL 2018:27:18, 18 (2018) (concluding “[t]he tobacco control community 
has been divided regarding the role of e-cigarettes in tobacco control. Our projections show that a strat-
egy of replacing cigarette smoking with vaping would yield substantial life year gains, even under pes-
simistic assumptions regarding cessation, initiation and relative harm”); KATHLEEN STRATTON ET AL., 
NAT’L ACADEMIES OF SCI., ENG’G, & MED., PUBLIC HEALTH CONSEQUENCES OF E-CIGARETTES, 15-16 
(2018). 
 44. E-cigarette or Vaping Product Use-Associated Lung Injury (EVALI), supra note 37. 
 45. See Outbreak of Lung Injury Associated with E-cigarette Use, or Vaping, CENTERS FOR DISEASE 
CONTROL (Feb. 25, 2020), https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-
disease.html#cdc-recommends [hereinafter Outbreak of Lung Injury Associated with E-cigarette Use]; 
Patrice A. Harris, M.D., M.A., AMA Urges Public to Avoid E-cigarette Use Amid Lung Illness Outbreak, 
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adolescent use of ENDS, nine states and more than 250 cities enacted or planned e-
cigarette bans or restrictions.46 The federal government also took action, with Pres-
ident Trump announcing a ban on the sale of flavored e-liquids except for tobacco 
and menthol for cartridge based devices and raising the minimum age to buy to-
bacco products from 18 to 21.47 Further research into EVALI, however, later re-
vealed that the disease was not caused by traditional e-cigarettes, but by Vitamin E 
acetate found in e-cigarettes containing THC.48 
The actions taken by federal and state governments to decrease adolescent us-
age of e-cigarettes seem to have been effective. The usage rates of 19.6% and 4.7% 
of high schoolers and middle schoolers in 2020, respectively, decreased from the 
2019 usage rates of 27.5% of high schoolers and 10.5% of middle schoolers.49 These 
actions are not without consequence, as stricter regulations and outright bans on 
these products may lead to an increase in traditional cigarette smokers and a de-
crease in cigarette cessation rates.50 Rather than imposing stricter limitations or ban-
ning these products, I propose providing an easier new drug pathway to market for 
ENDS products along with providing the current tobacco product pathways. This 
would allow ENDS to be marketed as cessation devices, with the flavored ENDS 
being the most common among adults attempting to quit traditional cigarettes,51 
while still reducing adolescent access to the devices. 
 
AMERICAN MEDICAL ASSOCIATION (Sep. 9, 2019), https://www.ama-assn.org/press-center/ama-state-
ments/ama-urges-public-avoid-e-cigarette-use-amid-lung-illness-outbreak. 
 46. See Terry Turner, Juul Ban, DRUGWATCH, https://www.drugwatch.com/e-cigarettes/juul-ban/ 
(last modified March 16, 2021). 
 47. Dan Vergano, Trump Just Announced A Nationwide Ban Of Flavored Vape Cartridges Except 
Tobacco And Menthol, BUZZFEED NEWS (Jan. 2, 2020 1:43 PM), https://www.buzzfeednews.com/arti-
cle/danvergano/trump-juul-flavor-ban. 
 48. See Outbreak of Lung Injury Associated with E-cigarette Use, supra note 45; Colin Poitras, Rates 
of E-cigarette and Marijuana Use Not Associated With Larger Outbreaks of Vaping-Related Lung Inju-
ries, YSPH Study Finds, YALE SCHOOL OF PUBLIC HEALTH (Aug. 25, 2020), https://publi-
chealth.yale.edu/news-article/26879/. 
 49. Wang et al., supra note 37, at 1310. 
 50. See generally Peter Hajek et al., A Randomized Trial of E-Cigarettes Versus Nicotine-Replacement 
Therapy, 380 N. ENGL. J. MED. 629, 629 (Jan. 30, 2019) (concluding “[e]-cigarettes were more effective 
for smoking cessation than nicotine-replacement therapy, when both products were accompanied by be-
havioral support”); Leonie S. Brose et al., Associations Between Vaping and Relapse to Smoking: Pre-
liminary Findings From a Longitudinal Survey in the UK, 16:76 HARM REDUCTION J. (Dec. 30, 2019),  
https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-019-0344-0 (concluding 
“[r]elapse to smoking is likely to be more common among ex-smokers vaping infrequently or using less 
advanced devices); Guy Bentley, Cigarette Sales Increase as Vaping Bans Push People Back to Smok-
ing, REASON FOUNDATION (Aug. 24, 2020), https://reason.org/commentary/cigarette-sales-increase-as-
vaping-bans-push-people-back-to-smoking/ (discussing potential results of the San Francisco ban on fla-
vored tobacco products potentially leading to loss in revenue and increase in traditional cigarette sales.) 
 51. Shannon Gravely, et al., The Association of E-cigarette Flavors With Satisfaction, Enjoyment, and 
Trying to Quit or Stay Abstinent From Smoking Among Regular Adult Vapers From Canada and the 
United States: Findings From the 2018 ITC Four Country Smoking and Vaping Survey, 22:10 NICOTINE 
AND TOBACCO RESEARCH 1831, 1834 (May 25, 2020). 
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II.     EXPLORING THE PATHWAYS TO MARKET 
A. Premarket Tobacco Product Applications and Substantial 
Equivalence 
New tobacco products can enter the market in one of three ways: (1) by show-
ing that the product is substantially equivalent to a previously approved tobacco 
product, (2) by showing that the product is exempt from showing substantial equiv-
alence, or (3) completion and acceptance of a premarket tobacco application 
(“PMTA”).52 
PMTA’s are required for any “new tobacco product”53 that a company intro-
duces or delivers for introduction into interstate commerce.54 For a PMTA to be 
accepted, a manufacturer must show that allowing their new tobacco product on the 
market would be “appropriate for the protection of the public health.”55 In deter-
mining whether the product is appropriate, the FDA takes into account “(A) the 
increased or decreased likelihood that existing users of tobacco products will stop 
using such products; and (B) the increased or decreased likelihood that those who 
do not use tobacco products will start using such products.”56 The manufacturing 
process of the product must also conform to good manufacturing practices under 
FDCA § 906 (e).57 A manufacturer’s labeling cannot be false or misleading, and 
must conform to the tobacco product standards found in FDCA § 907 or provide 
adequate information behind any change from the standards.58 
Virtually all ENDS are expected to reach the market through PMTA’s, due to 
the difficulty in identifying predicate ENDS products necessary for the substantial 
equivalence pathways.59 To show substantial equivalence, ENDS manufacturers 
would need to identify a predicate tobacco product that was “commercially mar-
keted (other than for test marketing) in the United States as of February 15, 2007.”60 
 
 52. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910, Pub. L. No. 111-31., 123 Stat. 1807 (1938) 
(codified as amended at 21 U.S.C. § 387(j) (2019)). 
 53. A new tobacco product is defined as “(A) any tobacco product (including those products in test 
markets) that was not commercially marketed in the United States as of February 15, 2007; or (B) any 
modification (including a change in design, any component, delivery, or form of nicotine, or any other 
additive or ingredient) of a tobacco product where the modified product was commercially marketed in 
the United States after February 15, 2007.” Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 
910(a)(1)(A)-(B), Pub. L. No. 111-31., 123 Stat. 1807 (1938) (codified as amended at 21 U.S.C. § 387(j) 
(a)(1)(A)-(B) (2019)). 
 54. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910, Pub. L. No. 111-31., 123 Stat. 1807 (1938) 
(codified as amended at 21 U.S.C. § 387(j) (2019)). 
 55. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910(c)(2)(A), Pub. L. No. 111-31., 123 Stat. 
1807 (1938) (codified as amended at 21 U.S.C. § 387(j)(c)(2)(A) (2019)). 
 56. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910(c)(4)(A)-(B), Pub. L. No. 111-31., 123 Stat. 
1807 (1938) (codified as amended at 21 U.S.C. § 387(j)(c)(4)(A)-(B) (2019)). 
 57. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910(c)(2)(B), Pub. L. No. 111-31., 123 Stat. 
1807 (1938) (codified as amended at 21 U.S.C. § 387(j)(c)(2)(B) (2019)). 
 58. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910(c)(2)(C)-(D), Pub. L. No. 111-31., 123 Stat. 
1807 (1938) (codified as amended at 21 U.S.C. § 387(j) (c)(2)(C)-(D) (2019)). 
 59. See generally Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910(a)(1)(A)-(B), Pub. L. No. 
111-31., 123 Stat. 1807 (1938) (codified as amended at 21 U.S.C. § 387(j) (a)(1)(A)-(B) (2019) (indi-
cating a predicate product existed before 2007); Grana et al., supra note 40 (indicating that E-cigarettes 
did not make it to American Markets until 2007). 
 60. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 910(a)(2)(A)(i)(I), Pub. L. No. 111-31., 123 
Stat. 1807 (1938) (codified as amended at 21 U.S.C. § 387(j)(a)(2)(A)(i)(I) (2019)). 
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Since modern e-cigarettes that could potentially be used as a predicate product to 
make a showing of substantial equivalence were not introduced into the American 
market until 2007, this is a virtually impossible showing to make.61 ENDS manu-
facturers likely could not argue that they are exempt from making a showing of 
substantial equivalence as the exemptions still require the locating of a predicate 
tobacco product that was commercially marketed as of February 15, 2007.62 This 
only leaves ENDS manufacturers with the PMTA process pathway to the market if 
they want to distribute their product as a tobacco product. 
As the September 9, 2020 deadline for ENDS manufactures to submit their 
PMTA’s drew closer, the cost of PMTA’s came under heavy criticism from the 
ENDS industry.63 The FDA contended that completion of a PMTA would cost a 
manufacturer around $117,00 to $466,000, but this was considered a low estimate 
by those in the industry, with Amanda Wheeler, vape store owner and vice president 
of Rocky Mountain Smoke-Free Alliance,64 estimating far more for these applica-
tion.65 And Joe Teller, category management director for Swedish Match, who com-
pleted eight PMTA’s for their General Snus line of smokeless tobacco stating that 
“[the cost] was more than what we thought for . . . PMTA.”66 The high cost on the 
companies stem from the FDA considering every different flavor variant and nico-
tine strength, and combination thereof, as a different tobacco product, and thus 
needing a separate PMTA.67 
B. New Drug Applications 
If the manufacturer does not want to distribute their product as a tobacco prod-
uct, there is also the option of distributing the tobacco product as a drug by going 
through the drug pathway to market.68 For ENDS manufacturers, this is currently 
not a viable option.69 Despite the shown benefits of ENDS products as tools for 
cigarette cessation, ENDS that claim health benefits would be considered an unap-
proved drug-device combination, and would have to undergo the requisite 
 
 61. See generally Grana et al., supra note 40 (indicating that E-cigarettes did not make it to American 
Markets until 2007). 
 62. See generally Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 905(j)(3)(A), Pub. L. No. 111-
31., 123 Stat. 1807 (1938) (codified as amended at 21 U.S.C. § 387(e)(j)(3)(A)(2019) (giving the re-
quirements to be exempt from such applications). 
 63. See Michael McGrady, As the PMTA Deadline Looms, the Vaping Industry Faces Potential Dis-
aster, INSIDE SOURCES (Sep. 3, 2020) https://www.insidesources.com/as-the-pmta-deadline-looms-the-
vaping-industry-faces-potential-disaster/. 
 64. Rocky Mountain Smoke-Free Alliance is a not-for-profit trade organization that represents small 
business owners and manufactures of ENDS in Colorado. See Advocating for Vapor Businesses is OUR 
business!, ROCKY MOUNTAIN SMOKE-FREE ALLIANCE, https://www.rmsfa.org/ (last visited April 2, 
2021); Meet Our Board, ROCKY MOUNTAIN SMOKE-FREE ALLIANCE, https://www.rmsfa.org/meet-our-
board (last visited April 2, 2021). 
 65. McGrady, supra note 63. 
 66. Melissa Vonder Haar, 6 Insights From CSP’s Tobacco Update Webinar, CSP DAILY NEWS (May 
25, 2016), https://www.cspdailynews.com/tobacco/6-insights-csps-tobacco-update-webinar#page=4. 
 67. U.S. FOOD & DRUG ADMIN., Commonly Asked Questions: About the Center for Tobacco Products, 
(July 10, 2020), https://www.fda.gov/tobacco-products/about-center-tobacco-products-ctp/commonly-
asked-questions-about-center-tobacco-products. 
 68. See infra notes 70-74 and accompanying text. 
 69. See infra notes 75-76 and accompanying text. 
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premarket review before they are allowed to reach the market.70 Whether a drug-
device combination product goes through the drug regulatory pathway or the device 
regulatory pathway depends on which part of the combination, the drug or device, 
contributes the most to the product’s intended therapeutic effect.71 For ENDS prod-
ucts that claim smoking cessation benefits, the drug product (the e-liquid) provides 
the claimed therapeutic effect, while the device portion is used to deliver the drug 
product.72 FDCA § 505(a) states that “no person shall introduce or deliver for intro-
duction into interstate commerce any new drug”73 without an approved New Drug 
Application (“NDA”), with a new drug being defined as a drug that is “not generally 
recognized. . . as safe and effective for use under the conditions prescribed, recom-
mended, or suggested in the labeling thereof.”74 Thus, an ENDS product that claims 
to be useful in smoking cessation would be a new drug subject to an NDA due to 
the products not being generally recognized as safe and effective for use as a smok-
ing cessation tool. 
NDA’s are even more costly than PMTA’s, with an estimated cost of $2.8 bil-
lion, as they have much stricter criteria for acceptance.75 For an NDA to be ap-
proved, the application needs to contain separate sections for clinical data on the 
drugs pharmacodynamics, efficacy, and safety; data from human pharmacokinetic 
studies; nonclinical studies; a full description of the manufacturing controls used; 
and the patent information of the product.76 The time and cost necessary for an NDA 
is only feasible for large tobacco corporations and preclude most manufacturers 
from using this route. 
C. Over-The Counter Monographs 
A potential third option for ENDS products to reach the market is through the 
use of an over-the-counter monograph (“OTC” monograph), which is what allows 
products such as nicotine gum and transdermal nicotine patches to be sold without 
a prescription.77 OTC monographs list the claims, labeling, dosages, and active in-
gredients of a product, and if the product matches everything on the list, allows it 
to be sold over-the-counter without a prescription.78 Drugs that are given OTC 
 
 70. See generally Smoking Everywhere Inc. v. U.S. Food and Drug Admin., 680 F.Supp.2d, 62, 63-71 
(2018); Hajek, supra note 50; Premarket Tobacco Product Applications, supra note 14, at 9; U.S. FOOD 
& DRUG ADMIN., Smoking Cessation and Related Indications: Developing Nicotine Replacement 
Therapy Drug Products, 3–4, (Feb. 2019), https://www.fda.gov/media/121308/download [hereinafter 
Smoking Cessation and Related Indications]. 
 71. 21 USC 353(g)(1)(C) (2018). 
 72. Smoking Cessation and Related Indications, supra note 70, at 4. 
 73. Food, Drug, and Cosmetic Act, ch. 675, Ch. V, § 505(a), Pub. L. No. 111-31., 123 Stat. 1807 
(1938) (codified as amended at 21 U.S.C. § 355(a) (2018). 
 74. Food, Drug, and Cosmetic Act, ch. 675, Ch. II, § 201(9), Pub. L. No. 111-31., 123 Stat. 1807 
(1938) (codified as amended at 21 U.S.C. § 3521(p) (2018). 
 75. See generally, Joseph A. DiMasi et al., Innovation in the Pharmaceutical Industry: New estimates 
of R&D costs, 47 J. OF HEALTH ECON. 20, 28 (May, 2016) (discussing the costs of development and 
clinical trial of drugs). 
 76. Food, Drug, and Cosmetic Act, ch. 675, Ch. V, § 505(b), Pub. L. No. 111-31., 123 Stat. 1807 
(1938) (codified as amended at 21 U.S.C. § 355(b) (2021). 
 77. See U.S. FOOD & DRUG ADMIN., Over-the-Counter (OTC) Drug Monograph Process, (Sept. 
3, 2020), https://www.fda.gov/drugs/over-counter-otc-drug-monograph-process [hereinafter Drug Mon-
ograph Process]. 
 78. See id. 
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monographs are generally regarded as safe and effective, meaning that they are not 
considered a “new drug” under FDCA 201(p), and do not require an NDA.79 As of 
the CARES Act, signed into law on March 27, 2020, the OTC monograph process 
is no longer subject to notice-and-comment rulemaking, and instead has adopted an 
administrative order process by which an order to add, remove, or change a mono-
graph can be either initiated directly by the FDA or requested by a company.80 The 
monograph is then reviewed by the FDA, and if accepted, codified in the Code of 
Federal Regulations.81 Once finalized, a company can market a drug that has an 
OTC monograph without going through the premarket approval process.82 
Usually, drugs that are given an OTC monograph were first prescription-only 
(Rx), and the manufacturer requested approval for OTC marketing.83 An Rx-to-
OTC switch requires the FDA to “look at the safety and effectiveness of the product, 
the benefit-to-risk ratio, and whether the labeling can be written in such a way that 
consumers can use the products safely without the intervention of a healthcare pro-
vider.”84 Individual drugs may also be granted OTC status, but not given an OTC 
monograph, as is the case with the current FDA approved OTC nicotine replace-
ment therapies (“NRT”).85 Each of the OTC NRT’s (nicotine gum, transdermal nic-
otine patches, and nicotine lozenges), became OTC through an Rx-to-OTC switch, 
meaning they originally went through the NDA pathway.86 
III.     AN OVER-THE-COUNTER MONOGRAPH FOR ENDS 
A. Benefits of an OTC Monograph 
An OTC monograph pathway for ENDS products would benefit manufactur-
ers, consumers, and public health more than the PMTA pathway or the NDA path-
way. Research has also shown that ENDS are more effective cigarette cessation 
tools than NRTs.87 A 2019 study published in the New England Journal of Medicine 
compared the cigarette cessation rates of various NRTs to ENDS and concluded 
that ENDS were more effective cigarette cessation tools than NRTs.88 The study 
found that “the 1-year abstinence rate was 18.0% in the e-cigarette group, as com-
pared with 9.9% in the nicotine-replacement group.”89 Researchers also generally 
 
 79. See id. 
 80. Id. 
 81. For the general provisions and administrative procedures regarding recognition of over-the-coun-
ter drug, see 21 C.F.R. § 330.1¬ (2020) – § 330.15 (2020). 
 82. Drug Monograph Process, supra note 77. 
 83. CONSUMER HEALTHCARE PRODUCTS ASS’N, https://www.chpa.org/about-consumer-
healthcare/faqs/FAQs-rx-otc-switch (last visited Mar. 6, 2021). 
 84. Id. 
 85. Azim Chowdhury & Samuel Jockel, Spotlight on Tobacco | Future Developments in the Regula-
tion of Electronic Nicotine Delivery Systems: Potential Over-the-Counter Pathway, FOOD & DRUG L. 
INST., https://www.fdli.org/2018/10/spotlight-on-tobacco-future-developments-in-the-regulation-of-
electronic-nicotine-delivery-systems-potential-over-the-counter-pathway/ (last visited Mar. 6, 2021); 
Nicotine replacement therapy, U.S. NAT’L LIBR. OF MED., https://medlineplus.gov/ency/arti-
cle/007438.htm (last visited Mar. 6, 2021). 
 86. See Chowdhury & Jockel, supra note 85. 
 87. Hajek, supra note 50, at 629. 
 88. Id. 
 89. Id. 
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regard ENDS as safer than traditional cigarettes.90 A 2017 study on the potential 
deaths averted in the United States by switching from traditional cigarettes to 
ENDS, under both pessimistic and optimistic models, found that “replacement of 
cigarette by e-cigarette use over a 10-year period yields 6.6 million fewer premature 
deaths with 86.7 million fewer life years lost in the Optimistic Scenario. Under the 
Pessimistic Scenario, 1.6 million premature deaths are averted with 20.8 million 
fewer life years lost.”91 
The benefits that an OTC monograph provides can be sorted into three catego-
ries: price, effectiveness as a cessation tool, and safety. 
i. Price 
One benefit of a monograph would be the potential to provide for a lower bar-
rier to entry for manufacturers entering into the ENDS market because each indi-
vidual product would no longer require premarket approval.92 Not needing pre-
market approval means that the monograph would be both a cheaper and more reli-
able pathway to market, as the manufacturer would not have to make the various 
costly showings required by PMTAs or NDAs.93 Instead, ENDS manufacturers 
would only need to match the contents of the monograph to reach the market.94 This 
lower entry barrier would likely lead to more competition in the market, as fewer 
companies would be forced out of the industry under a monograph than the current 
PMTA pathway.95 Easier access to the industry and more competition means that 
ENDS would likely be cheaper for consumers. As ENDS become cheaper, they will 
also become more attractive options to consumers wanting to quit smoking tradi-
tional cigarettes. 
ii. Effectiveness as a Cessation Tool 
An OTC monograph could allow for a wide assortment of flavors, or flavoring 
ingredients to be combined at the manufacturer’s discretion, which were often the 
manufacturer’s best-selling products.96 More variety in nontobacco flavored ENDS 
may improve their effectiveness as a cessation device.97 A 2020 study in Nicotine 
& Tobacco Research found that “[a] majority of regular vapers in Canada and the 
US use nontobacco flavors. Fruit and candy flavors lead to more satisfaction and 
enjoyment among users. While it does not appear that certain flavors are associated 
with a greater propensity to attempt to quit smoking among concurrent users, 
 
 90. Stratton, supra note 43, at 12 (“[t]he evidence about harm reduction suggests that across a range 
of studies and outcomes, e-cigarettes pose less risk to an individual than combustible tobacco ciga-
rettes.”) 
 91. Levy, supra note 43, at 18. 
 92. See Drug Monograph Process, supra note 77. 
 93. See supra notes 63-74 and accompanying text. 
 94. See Drug Monograph Process, supra note 77. 
 95. See McGrady, supra note 63. 
 96. See Victoria Forster, Study: Juul Stopped Selling Their Fruit-Flavored Vaping Pods, With No 
Effect On Overall Sales, FORBES (Apr. 17, 2020, 7:44 AM) https://www.forbes.com/sites/victoriafor-
ster/2020/04/17/study-juul-ceasing-sales-of-fruit-flavored-e-cigarettes-had-no-effect-on-overall-
sales/?sh=4f346d4c4cc5 (in October 2018, fruit flavors made up one-third of all sales of Juul flavors). 
 97. Gravely, supra note 51, at 1831-32. 
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nontobacco flavors are popular among former smokers who are exclusively vap-
ing.” 98 Flavored ENDS products are also the most popular among adolescents, and 
the limitations placed on flavored ENDS were enacted primarily to decrease ado-
lescent usage.99 An OTC monograph, combined with other sale restrictions, could 
combat this by placing limitations on where ENDS products could be sold, limiting 
the accessibility of the products to minors.100 
iii. Safety 
Perhaps the largest benefit of an OTC monograph pathway over the PMTA 
pathway for ENDS is that it would allow greater regulatory oversight over the health 
and safety of the products.101 Scott Gottlieb, the previous FDA Commissioner, 
stated in an interview with CNBC that: 
[An] over-the-counter regulatory pathway . . . would give us many more tools 
to look at both safety and benefit, and study whether or not an e-cigarette actually 
does promote smoking cessation and also give us many more tools to actually study 
the toxicology associated with it and see what effects it might have on the lung.102 
Although the availability of an OTC monograph for ENDS provides many clear 
benefits, there are three immediately apparent issues with the pathway. The issue of 
adolescent usage of ENDS, whether using ENDS to quit traditional nicotine prod-
ucts leads to long-term nicotine abstinence, and the barriers that are inherent to the 
creation of an OTC monograph for a drug. 
B. The Lingering Issue of Adolescent Use 
The issue of potential adolescent use of flavored ENDS could be mitigated by 
restricting the distribution of the products in ways where it would be more difficult 
for the adolescents to reach them, rather than wholly taking the products off of the 
market or imposing the costly burden that is a PMTA. A major step towards this 
has already been accomplished with the nationwide T21 laws enacted on December 
20, 2019, amending the FDCA by raising the minimum legal age for tobacco prod-
ucts from 18 years-old to 21 years-old.103 Prior to the amendment, nineteen states 
raised the state-wide minimum legal age for tobacco products to 21, with Hawaii 
and California being the first to implement T21 laws on January 1, 2016, and June 
9, 2016, respectively.104 Although it is too early to know the substantive effects of 
the FDCA amendment, the results of the state-led T21 laws have been mixed. The 
 
 98. Id. at 1832. 
 99. Vergano, supra note 47. 
 100. See infra notes 105-113 and accompanying text. 
 101. See Angelica LaVito, FDA may consider over-the-counter regulation for e-cigarettes, CNBC 
(Mar. 28, 2018 10:16 AM), https://www.cnbc.com/2018/03/28/fda-may-consider-over-the-counter-reg-
ulation-for-e-cigarettes.html. 
 102. Id. 
 103. Food, Drug, and Cosmetic Act, ch. 675, Ch. IX, § 906(d), Pub. L. No. 111-31., 123 Stat. 1807 
(1938) (codified as amended at 21 U.S.C. § 387f(d)(3)(A)(ii) (2019). 
 104. CTR. FOR DISEASE CONTROL, Tobacco 21: Policy Evaluation for Comprehensive Tobacco Con-
trol Programs 4-5, https://www.cdc.gov/tobacco/stateandcommunity/tobacco_control_programs/sur-
veillance_evaluation/tobacco-21-policy-evaluation/pdfs/T21-policy-evaluation-guide-508.pdf (last vis-
ited April 2, 2021); Xueying Zhang, et al., Evaluation of California’s ‘Tobacco 21’ law, TOBACCO 
CONTROL 2018:27:656, 656 (2018). 
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results of a study published January 13, 2020 revealed that “[f]ollowing the T21 in 
Hawaii, average monthly cigarette unit sales dropped significantly (−4.4%, p<0.01) 
coupled with a significant decrease in menthol market share (−0.8, p<0.01),” and 
concluded that “[a]s part of a comprehensive approach to prevent or delay tobacco 
use initiation, T21 laws may help to reduce sales of cigarette and large cigar prod-
ucts most preferred by US youth and young adults.”105 These results are not across 
the board, however, as a February 27, 2020 study on the effects of the T21 laws in 
California found “[n]egligible changes in cigarette and e-cigarette use. . . observed 
pre-T21 versus post-T21,” and concluded that “[p]ost-T21, few participants were 
refused purchase of any tobacco product, despite the illegality of such sales. Better 
enforcement of T21 is needed to improve the efficacy of T21 legislation.”106 As the 
long-term effects of T21 laws are not yet certain, further limitations need to be im-
plemented in the distribution of ENDS to reduce the availability of the products to 
minors before additional flavored ENDS, which are favored by both adolescents 
and adults attempting to quit traditional cigarettes, should reach the market.107 If 
classified as an OTC product, there is already the groundwork for a model distribu-
tion method for ENDS as a cessation device rather than a tobacco product in the 
distribution limitations that the FDA placed on Nicorette (nicotine gum) during their 
switch from prescription drug to OTC.108 The FDA restricted the sale of Nicorette 
to drugstores, mass merchandisers, and supermarkets, and prohibited its sale in con-
venience stores such as gas stations.109 The FDA also required the company to not 
sell “trial size” or “sample” packs, package each piece of gum in child resistant 
packaging, offer incentives to retailers to place Nicorette with the other OTC drugs, 
and provide a smoking cessation program in the form of a toll-free phone number 
on the packaging.110 
For ENDS products, the limitations of restricting the sale to drugstores, mass 
merchandisers, and supermarkets, and prohibiting their sale in conveniences stores, 
coupled with a limitation on the online sales of the products, would arguably have 
the greatest impact in keeping the products out of reach for adolescents. In 2019, 
three-fourths of adolescents who used Juul, the most commonly sold e-cigarette 
brand, obtained the product at a physical retail location, and approximately half of 
all e-cigarette sales in the United States were through vape shops111 or the 
 
 105. Rebecca Glover-Kudon, et al., Cigarette and cigar sales in Hawaii before and after implementa-
tion of a Tobacco 21 Law, TOBACCO CONTROL 2021:30:98, 98 (2021). 
 106. Sara Schiff, et al., E-cigarette and cigarette purchasing among young adults before and after im-
plantation of California’s tobacco 21 policy, TOBACCO CONTROL 2021:30:206, 206 (2021). 
 107. Gravely, supra note 51, at 1831. 
 108. See letter from Debra L. Bowen, M.D., Acting Director, Division of Over-the Counter Drug Prod-
ucts, and Cynthia G. McCormick, M.D., Director, Division of Anesthetic, Critical Care, and Addiction 
Drug Products, to David Schifkovitz, Associate Director, Regulatory Affairs, SmithKline Beecham Con-
sumer Healthcare (Dec. 23, 1998), https://www.accessdata.fda.gov/drugsatfda_docs/nda/98/18-
612S025_Nicorette_Approv.pdf (OTC approval letter to Nicorette that places marketing limitations on 
the product). 
 109. See id. 
 110. See id. 
 111. A “Vape Shop” is a physical retail store that “sells products such as vape pens, tanks, mods, e-
juices, e-hookahs, advanced systems, and their accompanying components along with e-liquid solutions 
or cartridges. These stores may or may not have a vaping lounge or vaping bar inside as well. Many vape 
shops operate on non-traditional retail hours, opening closer to noon and closing later at night.” See E-
Cigarettes at the Point of Sale, COUNTER TOBACCO, https://countertobacco.org/resources-tools/evi-
dence-summaries/e-cigarettes-at-the-point-of-sale/ (last visited April 2, 2021) [hereinafter E-Cigarettes 
at the Point of Sale]. 
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internet.112 A 2018 study showed that, in California, tobacco and vape shops had 
the highest rate of sales of vape products to underage adolescent decoys than any 
other retailer type at 44.7%.113 Internet retail poses a similar problem, where a sig-
nificant number of middle and high schoolers obtained their e-cigarettes online,114 
and a 2015 study finding that “minors successfully received deliveries of e-ciga-
rettes from 76.5% of purchase attempts, with no attempts by delivery companies to 
verify their ages at delivery.”115 Conversely, according to the same 2018 California 
study, pharmacies had the lowest failure to check identification for e-cigarettes rate 
at approximately 10%, and small markets and supermarkets had the lowest violation 
rate for underage e-cigarettes at approximately 12%.116 As such, placing distribu-
tion limitations on ENDS similar to those that are already placed on Nicorette, 
which restricts the sales of the product to drug stores, mass merchandisers, and su-
permarkets, combined with the T-21 laws and the prohibition of online sales of 
ENDS, would likely have a large beneficial impact in keeping the products out of 
the hands of adolescents. 
C. ENDS and Nicotine Abstinence 
The overall goal of ENDS as cessation tools would be complete abstinence 
from nicotine, rather than trading one addiction for another. To be an effective tool 
for eventual nicotine abstinence, the addictiveness of ENDS would need to be com-
parable to other NRTs such as nicotine gum or transdermal nicotine patches, and 
less addictive than traditional tobacco products.117 There does not seem to be a gen-
eral consensus in the scientific community yet as to whether using ENDS as a cig-
arette cessation tool leads to a continuing dependence on nicotine.118 
D. Barriers to ENDS as an Over-the-Counter Drug 
Perhaps the largest obstacle for ENDS to be given an OTC monograph is that 
they would first have to be generally regarded as safe and effective (“GRASE”) 
before they can be given a monograph, and it may not be enough that they are both 
generally regarded to be safer than traditional cigarettes and have shown to be a 
better cigarette cessation tool than current NRTs.119 For a drug to be considered 
GRASE: 
 
 112. See Fatma Romeh, et al., E-cigarette Unit Sales, by Product and Flavor Type — United States, 
2014–2020, 69 MORBIDITY & MORTALITY WEEKLY REPORT 1313, 1316 (Sep. 18, 2020). 
 113. E-Cigarettes at the Point of Sale, supra note 111. 
 114. Where do Youth get their E-Cigarettes?, TOBACCO FREE KIDS, https://www.tobaccofreek-
ids.org/assets/factsheets/0403.pdf (last visited April 2, 2021). 
 115. Rebecca S. Williams, et al., Electronic Cigarette Sales to Minors via the Internet, JAMA 
PREDIATR. 2015:169(3):e1563, 1563 (March 2, 2015), https://jamanetwork.com/journals/jamapediat-
rics/article-abstract/2174572. 
 116. E-Cigarettes at the Point of Sale, supra note 111. 
 117. See generally Chowdhury & Jockel, supra note 85 (explaining the NRT process). 
 118. See generally e.g. Chen, at al., Use of Electronic Cigarettes to Aid Long-Term Smoking Cessation 
in the United States: Prospective Evidence From the PATH Cohort Study, AM. J. OF EPIDEMIOLOGY 
2020:189(12): 1529, 1529 (July 2020) (concluding that ENDS “may contribute to continuing nicotine 
dependence.”); Guodong Liu, et al., A Comparison of Nicotine Dependence among Exclusive E-cigarette 
and Cigarette Users in the PATH Study, PREV. MED. November:104:86, 86 (2017) (that “everyday ex-
clusive e-cig users report lower dependence than comparable cigarette users.”). 
 119. See Chowdhury & Jockel, supra note 85; Hajek, supra note 50, at 629. 
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First, the particular drug product must have been subjected to adequate and 
well-controlled clinical investigations that establish the product as safe and effec-
tive. 
Second, those investigations must have been published in the scientific litera-
ture available to qualified experts. 
Third, experts must generally agree, based on those published studies, that the 
product is safe and effective for its intended uses. At a minimum, the general ac-
ceptance of a product as GRASE must be supported by the same quality and quan-
tity of scientific and/or clinical data necessary to support the approval of a New 
Drug Application.120 
Requiring the same amount and quality of data as an NDA is a high bar, and 
an issue with ENDS lies in the relative recentness with which they appeared on the 
market.121 The other OTC smoking cessation products, nicotine gum, nicotine loz-
enges, and nicotine patches, have all been on the market much longer than ENDS, 
with nicotine lozenges, approved in 2002, being the most recent.122 ENDS products 
have only been on the market since 2007, and there is still a great amount of uncer-
tainty over the long-term effects of the products.123 Also, as mentioned above, an 
NDA may be prohibitively expensive for more ENDS manufacturers.124 As the vast 
majority of ENDS manufacturers would not be able to afford this process, either 
one of the top ENDS manufacturers (who are likely the least affected by the PMTA 
requirements) would need to make the request to the FDA and collect the data, or 
the FDA would need to initiate the process on their own accord through an admin-
istrative order.125 
IV.     CONCLUSION 
An OTC monograph for ENDS would allow manufacturers to market the prod-
ucts to their full potential as cessation devices for a low cost, would make ENDS 
accessible for adults while also providing a barrier against underage use, and would 
allow for more regulatory oversight as to the safety of the products. Providing an-
other safe tool to help the millions of American’s overcome their addiction to tra-
ditional cigarettes, while preventing nonsmokers and adolescents from developing 
a nicotine addiction, should be among the top priorities of the United States. Alt-
hough cigarette smoking rates in the United States have decreased from 20.9% in 
2005, to 14.0% in 2019, it is still the leading cause of preventable deaths at 480,000 
a year.126 Nicotine is among the most addictive substances in the world, and in 2018 
only 7.5% of the 34.2 million Americans that smoked cigarettes managed to quit 
successfully.127 
 
 120. U.S. FOOD & DRUG ADMIN., GRASE, https://www.accessdata.fda.gov/scripts/cder/train-
ing/otc/topic3/topic3/da_01_03_0040.htm (last visited April 2, 2021). 
 121. See Grana et al., supra note 40. 
 122. See Chowdhury & Jockel, supra note 85. 
 123. See Grana et al., supra note 40; Stratton, supra note 43, at 21. 
 124. See supra notes 63-67 and accompanying text. 
 125. See generally Drug Monograph Process, supra note 77. 
 126. CTR. FOR DISEASE CONTROL, Current Cigarette Smoking Among Adults in the United States (last 
updated Dec. 10, 2020), https://www.cdc.gov/tobacco/data_statistics/fact_sheets/adult_data/cig_smok-
ing/index.htm. 
 127. 5 Most Addictive Drugs, AMERICAN ADDICTION CENTERS, https://americanaddiction-
centers.org/adult-addiction-treatment-programs/most-addictive (last updated Feb. 22, 2021); CTR. FOR 
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ENDS have the potential to be the most effective cigarette cessation tool on the 
market, and even under pessimistic models of long-term health effects, the complete 
replacement of traditional cigarettes with ENDS would save approximately 1.6 mil-
lion lives over a 20-year period.128 The current pathways to market for the products, 
however, do not allow ENDS to live up to this life-saving potential. The available 
tobacco pathway for ENDS, PMTA’s, limit the manufacturers to not allow them to 
market the products as cessation devices. If the manufacturer wants to market their 
ENDS product as a cessation tool, they must complete an NDA, which is much too 
expensive, and would only allow for ENDS products to be sold with a prescription, 
severely limiting their accessibility. Perhaps the largest barrier to ENDS obtaining 
an OTC monograph is the lack of a scientific consensus on the long-term health 
effects of the products.129 Paradoxically, an OTC monograph would give the FDA 
more oversight in the research of the products.130 Regardless, the scientific consen-
sus on ENDS products is that they are overall safer than traditional cigarettes, and 
any step towards safely decreasing the number of traditional tobacco users in the 
United States is a step that should be taken.131 
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